Top

Infectious Diseases and Therapy

Published in:

Open Access 09-01-2024 | Shingles | Original Research

Incidence and Burden of Herpes Zoster in Sweden: A Regional Population-Based Register Study

Authors: Emma Södergren, Kristina Mårdberg, Marie Nishimwe, Amit Bhavsar, Alen Marijam, Tomas Bergström, Patrik Stäck

Published in: Infectious Diseases and Therapy | Issue 1/2024

Abstract

Introduction

Herpes zoster (HZ) is a painful disease that mainly affects individuals whose immune system has been weakened because of increasing age (> 50 years) or certain diseases or treatments. We estimated the complete burden of HZ.

Methods

This population-based register study analysed healthcare data from the VEGA and Digitalis databases of Västra Götaland Region (VGR), Sweden. The VEGA database includes all patients in VGR, covering both hospital and primary care. The Digitalis records prescribed medications. The study population included patients aged ≥ 18 years with at least one registered primary or secondary HZ diagnosis (based on International Classification of Diseases [ICD] codes) between 2005 and 2021. Incidence rates (95% confidence intervals [CI]) were stratified by age, sex and diagnosis/analgesic prescription.

Results

Overall HZ incidence increased from 2.5 (95% CI 2.4–2.6) in 2005 to 4.2 (95% CI 4.1–4.3) in 2021. The increase in incidence was rapid from 2005 to 2013, followed by a plateauing trend. From 2014–2019, the lifetime risk of HZ, excluding recurrent cases, was 36.5% (95% CI 35.5–37.4%). Municipal differences ranged from 34.4% (95% CI 32.5–36.4%) to 43.6% (95% CI 39.9–47.4%). Recurrence rates of HZ were 8.7% and 9.1% with follow-up periods of 5.5 and 10.5 years, respectively. Reported postherpetic neuralgia (PHN) cases increased five-fold over the study period. In 2019, 19% of all HZ patients developed HZ-related neuropathic pain; 13.6% had signs of persistent pain (> 90 days; i.e. PHN). An increased occurrence of cerebral and cardiovascular disease was observed in HZ patients. Among high-risk groups the occurrence of HZ peaked among those with inflammatory and autoimmune diseases.

Conclusion

HZ and PHN risk in Sweden is comparable to that in other European countries prior to implementing HZ national vaccination programs. Municipal differences suggest that the lifetime risk of HZ in Sweden is at least 36.5%.

Clinical Trial Registration

NCT Number (www.clinicaltrials.gov).

Graphical Abstract

Available only for authorised users

Svahn A, Berggren J, Parke A, Storsaeter J, Thorstensson R, Linde A. Changes in seroprevalence to four herpesviruses over 30 years in Swedish children aged 9–12 years. J Clin Virol. 2006;37(2):118–23. https://doi.org/10.1016/j.jcv.2006.07.012.CrossRefPubMed

Hope-Simpson RE. The nature of herpes zoster: A long-term study and a new hypothesis. Proc R Soc Med. 1965;58(1):9–20.PubMedPubMedCentral

Whitley RJ. Herpesviruses. In: Baron S, editor. Medical microbiology. Galveston: University of Texas Medical Branch at Galveston; 1996.

Centers for Disease Control and Prevention. Varicella. https://www.cdc.gov/vaccines/pubs/pinkbook/varicella.html#:~:text=Varicella%20is%20an%20acute%20infectious,end%20of%20the%2019th%20century. Accessed 26 Aug 2023.

Bowsher D. The lifetime occurrence of Herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population. Eur J Pain. 1999;3(4):335–42. https://doi.org/10.1053/eujp.1999.0139.CrossRefPubMed

Drolet M, Oxman MN, Levin MJ, et al. Vaccination against herpes zoster in developed countries: state of the evidence. Hum Vaccin Immunother. 2013;9(5):1177–84. https://doi.org/10.4161/hv.23491.CrossRefPubMedPubMedCentral

Drolet M, Brisson M, Levin MJ, et al. A prospective study of the herpes zoster severity of illness. Clin J Pain. 2010;26(8):656–66. https://doi.org/10.1097/AJP.0b013e3181eef686.CrossRefPubMed

Pinchinat S, Cebrián-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013;13(1):170. https://doi.org/10.1186/1471-2334-13-170.CrossRefPubMedPubMedCentral

van Oorschot D, Vroling H, Bunge E, Diaz-Decaro J, Curran D, Yawn B. A systematic literature review of herpes zoster incidence worldwide. Hum Vaccin Immunother. 2021;17(6):1714–32. https://doi.org/10.1080/21645515.2020.1847582.CrossRefPubMedPubMedCentral

10.

Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127(2):305–14. https://doi.org/10.1017/s0950268801005921.CrossRefPubMedPubMedCentral

11.

Strategic Advisory Group of Experts on Immunization (SAGE). SAGE Yellow Book. Background paper herpes zoster vaccines. 20214. https://www.who.int/news-room/events/detail/2014/04/01/default-calendar/strategic-advisory-group-of-experts-on-immunization-(sage)---april-2014. Accessed 25 Aug 2023.

12.

World Health Organization. Varicella and herpes zoster vaccines: WHO position paper, June 2014. Wkly Epidemiol Rec. 2014;89(25):265–87.

13.

Centers for Disease Control and Prevention. Shingles (Herpes Zoster). https://www.cdc.gov/shingles/surveillance.html. Accessed August 10, 2023.

14.

Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6): e004833. https://doi.org/10.1136/bmjopen-2014-004833.CrossRefPubMedPubMedCentral

15.

Johnson RW, Alvarez-Pasquin MJ, Bijl M, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015;3(4):109–20. https://doi.org/10.1177/2051013615599151.CrossRefPubMedPubMedCentral

16.

Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24(4):494–500. https://doi.org/10.1016/j.coi.2012.06.002.CrossRefPubMed

17.

Chen SY, Suaya JA, Li Q, et al. Incidence of herpes zoster in patients with altered immune function. Infection. 2014;42(2):325–34. https://doi.org/10.1007/s15010-013-0550-8.CrossRefPubMed

18.

Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(5):1–30.PubMed

19.

Batram M, Witte J, Schwarz M, et al. Burden of Herpes Zoster in adult patients with underlying conditions: analysis of German claims data, 2007–2018. Dermatol Ther (Heidelb). 2021;11(3):1009–26. https://doi.org/10.1007/s13555-021-00535-7.CrossRefPubMed

20.

Esteban-Vasallo MD, Domínguez-Berjón MF, Gil-Prieto R, Astray-Mochales J, Gil-de-Miguel A. Sociodemographic characteristics and chronic medical conditions as risk factors for herpes zoster: a population-based study from primary care in Madrid (Spain). Hum Vaccin Immunother. 2014;10(6):1650–60. https://doi.org/10.4161/hv.28620.CrossRefPubMedPubMedCentral

21.

Forbes HJ, Bhaskaran K, Thomas SL, Smeeth L, Clayton T, Langan SM. Quantification of risk factors for herpes zoster: population based case-control study. BMJ. 2014;348: g2911. https://doi.org/10.1136/bmj.g2911.CrossRefPubMedPubMedCentral

22.

Huang CT, Lee CY, Sung HY, Liu SJ, Liang PC, Tsai MC. Association Between Diabetes Mellitus and the Risk of Herpes Zoster: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2022;107(2):586–97. https://doi.org/10.1210/clinem/dgab675.CrossRefPubMed

23.

Muñoz-Quiles C, López-Lacort M, Díez-Domingo J, Orrico-Sánchez A. Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009–2014. BMC Infect Dis. 2020;20(1):905. https://doi.org/10.1186/s12879-020-05648-6.CrossRefPubMedPubMedCentral

24.

Steindel SJ. International classification of diseases, 10th edition, clinical modification and procedure coding system: descriptive overview of the next generation HIPAA code sets. J Am Med Inform Assoc. 2010;17(3):274–82. https://doi.org/10.1136/jamia.2009.001230.CrossRefPubMedPubMedCentral

25.

Statistics Sweden. Population Statistics. 2023. https://www.scb.se/en/finding-statistics/statistics-by-subject-area/population/population-composition/population-statistics/. Accessed 11 Aug, 2023

26.

The National Board of Health and Welfare. Statistical database for causes of death. 2023. https://sdb.socialstyrelsen.se/if_dor/val.aspx. Accessed 05 July 2023.

27.

The Swedish National Airway Register. Swedish National Airway Register. https://lvr.registercentrum.se/. Accessed 05 July 2023.

28.

Swedish Social Insurance Agency. Disability Pension for Persons with Herpes Zoster, 2003–2020. https://www.forsakringskassan.se/. Accessed 10 Aug 2023.

29.

Swedish Social Insurance Agency. Sick leave statistics for herpes zoster, 2015–2021. 2023. https://www.forsakringskassan.se/. Accessed 10 Aug 2023

30.

The Swedish National Diabetes Register. Swedish National Diabetes Register. 2023. https://www.ndr.nu/#/. Accessed 05 July 2023.

31.

Hillebrand K, Bricout H, Schulze-Rath R, Schink T, Garbe E. Incidence of herpes zoster and its complications in Germany, 2005–2009. J Infect. 2015;70(2):178–86. https://doi.org/10.1016/j.jinf.2014.08.018.CrossRefPubMed

32.

Sundström K, Weibull CE, Söderberg-Löfdal K, Bergström T, Sparén P, Arnheim-Dahlström L. Incidence of herpes zoster and associated events including stroke-a population-based cohort study. BMC Infect Dis. 2015;15:488. https://doi.org/10.1186/s12879-015-1170-y.CrossRefPubMedPubMedCentral

33.

Sasieni PD, Adams J. Standardized lifetime risk. Am J Epidemiol. 1999;149(9):869–75. https://doi.org/10.1093/oxfordjournals.aje.a009903.CrossRefPubMed

34.

Statistics Sweden. Care Need Index (CNI). https://www.scb.se/vara-tjanster/bestall-data-och-statistik/regionala-statistikprodukter/care-need-index-cni/. Accessed 11 Aug 2023.

35.

The R foundation. The R Project for Statistical Computing. https://www.r-project.org/. Accessed 02 Nov 2022.

36.

Backman H, Vanfleteren L, Lindberg A, et al. Decreased COPD prevalence in Sweden after decades of decrease in smoking. Respir Res. 2020;21(1):283. https://doi.org/10.1186/s12931-020-01536-4.CrossRefPubMedPubMedCentral

37.

Region Stockholm. Asthma in children and adults - diagnostics, treatment and follow-up. https://kunskapsstodforvardgivare.se/download/18.5242224a17ce9bd8a66c0/1636015511620/Astma%20hos%20barn%20och%20vuxna.pdf. Accessed 26 Aug 2023.

38.

Backman H, Räisänen P, Hedman L, et al. Increased prevalence of allergic asthma from 1996 to 2006 and further to 2016-results from three population surveys. Clin Exp Allergy. 2017;47(11):1426–35. https://doi.org/10.1111/cea.12963.CrossRefPubMed

39.

Soriano JB, Alfageme I, Miravitlles M, et al. Prevalence and determinants of COPD in Spain: EPISCAN II. Arch Bronconeumol (Engl Ed). 2021;57(1):61–9. https://doi.org/10.1016/j.arbres.2020.07.024.CrossRefPubMed

40.

Sveréus S, Bergfors S, Dahlgren C, Rehnberg C. Mapping registry-based COPD prevalence, care utilization and opportunities for quality management in Stockholm county council. http://dok.slso.sll.se/CES/FHG/Tobak/Rapporter/kartlaggning-av-registerbaserad-KOL-prevalens.2013.pdf. Accessed 26 Aug 2023.

41.

Anell A. Choice and privatisation in Swedish primary care. Health Econ Policy Law. 2011;6(4):549–69. https://doi.org/10.1017/S1744133110000216.CrossRefPubMed

42.

Persson A, Bergström T, Lindh M, Namvar L, Studahl M. Varicella-zoster virus CNS disease–viral load, clinical manifestations and sequels. J Clin Virol. 2009;46(3):249–53. https://doi.org/10.1016/j.jcv.2009.07.014.CrossRefPubMed

43.

The Public Health Authority (Fohm). Vaccination against shingles (herpes zoster). https://www.folkhalsomyndigheten.se/smittskydd-beredskap/vaccinationer/vacciner-som-anvands-i-sverige/baltros/. Accessed 14 April 2023.

44.

Källmark H, Bergström T, Nagel J, et al. Serologic immunogenicity and safety of Herpes Zoster subunit vaccine in patients with Rheumatoid Arthritis receiving Janus Kinase inhibitors. Rheumatology (Oxford). 2023. https://doi.org/10.1093/rheumatology/kead552.CrossRefPubMed

45.

Siedler A, Koch J, Ultsch B, et al. Background paper to the decision not to recommend a standard vaccination with the live attenuated herpes zoster vaccine for the elderly in Germany : Statement of the German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute (RKI). Bundesgesundheitsbl. 2017;60(10):1162–79.CrossRef

46.

UK Health Security Agency. Shingles (herpes zoster): the green book, chapter 28a. https://www.gov.uk/government/publications/shingles-herpes-zoster-the-green-book-chapter-28a. Accessed 06 Dec 2022.

47.

Gauthier A, Breuer J, Carrington D, Martin M, Rémy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect. 2009;137(1):38–47. https://doi.org/10.1017/s0950268808000678.CrossRefPubMed

48.

Curran D, Matthews S, Boutry C, Lecrenier N, Cunningham AL, Schmader K. Natural history of herpes zoster in the placebo groups of three randomized phase III clinical trials. Infect Dis Ther. 2022;11(6):2265–77. https://doi.org/10.1007/s40121-022-00689-7.CrossRefPubMedPubMedCentral

49.

Muñoz-Quiles C, López-Lacort M, Orrico-Sánchez A, Díez-Domingo J. Impact of postherpetic neuralgia: a six year population-based analysis on people aged 50 years or older. J Infect. 2018;77(2):131–6. https://doi.org/10.1016/j.jinf.2018.04.004.CrossRefPubMed

50.

Mardberg K, Kanerva M, Heinonen S, et al. (2022) Herpes Zoster incidence among adults in Sweden, Denmark and Finland from 2014 to 2019: A preliminary analysis of the public healthcare sector databases. Nordic Society of Clinical Microbiology & Infectious Diseases- 38 Annual meeting. Aalborg, Denmark: NSCMID; 2022.

51.

Parikh R, Widenmaier R, Lecrenier N. A practitioner’s guide to the recombinant zoster vaccine: review of national vaccination recommendations. Expert Rev Vaccines. 2021;20(9):1065–75. https://doi.org/10.1080/14760584.2021.1956906.CrossRefPubMed

52.

European Centre for Disease Prevention and Control (ECDC). Herpes Zoster: Recommended vaccinations. https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=51&SelectedCountryIdByDisease=-1. Accessed November 09 2023.

53.

Wolff E, Widgren K, Scalia Tomba G, Roth A, Lep T, Andersson S. Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: an economic evaluation using a dynamic transmission model. PLoS ONE. 2021;16(5): e0251644. https://doi.org/10.1371/journal.pone.0251644.CrossRefPubMedPubMedCentral

Title: Incidence and Burden of Herpes Zoster in Sweden: A Regional Population-Based Register Study
Authors: Emma Södergren
Kristina Mårdberg
Marie Nishimwe
Amit Bhavsar
Alen Marijam
Tomas Bergström
Patrik Stäck
Publication date: 09-01-2024
Publisher: Springer Healthcare
Keyword: Shingles
Published in: Infectious Diseases and Therapy / Issue 1/2024
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI: https://doi.org/10.1007/s40121-023-00902-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Clinical Trial Registration

Graphical Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Nirmatrelvir/Ritonavir Utilization for the Treatment of Non-hospitalized Adults with COVID-19 in the National Veterans Affairs (VA) Healthcare System

Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies

Remdesivir for the Treatment of COVID-19: A Narrative Review

Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection

Navigating the Complex Landscape of Ebola Infection Treatment: A Review of Emerging Pharmacological Approaches

Safety and Effectiveness of Molnupiravir in Japanese Patients with COVID-19: Final Report of Post-marketing Surveillance in Japan

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials